These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28142249)

  • 1. Commentary on Fleming et al.: Data monitoring committee evidence base needed.
    Terrin M
    Clin Trials; 2017 Apr; 14(2):124-125. PubMed ID: 28142249
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on DeMets et al: The need for greater transparency regarding data monitoring committee charters.
    Shah SK; Eckstein L; Ibrahim A
    Clin Trials; 2023 Aug; 20(4):452-454. PubMed ID: 37231704
    [No Abstract]   [Full Text] [Related]  

  • 3. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on Anand et al.
    Dixon DO
    Clin Trials; 2011 Dec; 8(6):720-1; discussion 726. PubMed ID: 22167108
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary on Anand et al.
    DeMets DL
    Clin Trials; 2011 Dec; 8(6):722-3; discussion 726. PubMed ID: 22167109
    [No Abstract]   [Full Text] [Related]  

  • 6. Commentary on Anand et al.
    Califf RM
    Clin Trials; 2011 Dec; 8(6):724-5; discussion 726. PubMed ID: 22167110
    [No Abstract]   [Full Text] [Related]  

  • 7. Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    Clin Trials; 2008; 5(4):364-5; author reply 365-6. PubMed ID: 18697851
    [No Abstract]   [Full Text] [Related]  

  • 8. The Data Monitoring Committee: A Collective or a Collection?
    Wittes J; Fleming T; DeMets D; Ellenberg S; Gerstein H; Pfeffer M; Rockhold F; Yusuf S; Hennekens C
    Ther Innov Regul Sci; 2023 Jul; 57(4):653-655. PubMed ID: 37069466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees.
    ; Dixon DO; Freedman RS; Herson J; Hughes M; Kim K; Silverman MH; Tangen CM
    Clin Trials; 2006; 3(3):314-9. PubMed ID: 16895048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees.
    ; ;
    Stat Med; 2006 May; 25(10):1639-45. PubMed ID: 16639775
    [No Abstract]   [Full Text] [Related]  

  • 13. Commentary: data monitoring confidentiality and FDA transparency.
    London AJ
    Clin Trials; 2015 Feb; 12(1):12-4. PubMed ID: 25525073
    [No Abstract]   [Full Text] [Related]  

  • 14. Issues in regulatory guidelines for data monitoring committees.
    DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R
    Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What information should a sponsor of a randomized trial receive during its conduct?
    Anand SS; Wittes J; Yusuf S
    Clin Trials; 2011 Dec; 8(6):716-9. PubMed ID: 22024103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data monitoring and safety committees and their operations.
    Rouse DJ
    Obstet Gynecol Surv; 2003 May; 58(5):329-36. PubMed ID: 12719675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks in Randomized Controlled Trials: Role of Interim Analysis and Data Monitoring Committee.
    Naqvi HA
    J Coll Physicians Surg Pak; 2015 Aug; 25(8):557-9. PubMed ID: 26305298
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary: preserving confidentiality of interim data.
    Chuang-Stein C; Jiang Q; Marchenko O
    Clin Trials; 2015 Feb; 12(1):18-20. PubMed ID: 25480540
    [No Abstract]   [Full Text] [Related]  

  • 19. Commentary: confidentiality of interim trial data-the emerging crisis.
    Nissen SE
    Clin Trials; 2015 Feb; 12(1):15-7. PubMed ID: 25525072
    [No Abstract]   [Full Text] [Related]  

  • 20. Shedding light on data monitoring committee charters on ClinicalTrials.gov.
    Fine AM; Golfinopoulos E; Tse T
    Clin Trials; 2024 Apr; 21(2):260-261. PubMed ID: 37924275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.